A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00631150|
Recruitment Status : Completed
First Posted : March 7, 2008
Last Update Posted : November 15, 2013
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Epilepsy||Drug: Levetiracetam (Keppra)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy|
|Study Start Date :||March 2003|
|Actual Primary Completion Date :||July 2004|
|Actual Study Completion Date :||July 2004|
- Safety and the tolerability of Keppra in a broad population of patients.
- Obtain further information about optimal daily dose.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||16 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- partial onset seizures with or without secondary generalisation with epilepsy.
- hypersensitivity to levetiracetam or other pyrrolidone derivatives or to any of the excipients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00631150
|Study Director:||UCB Clinical Trial Call Center||+1 877 822 9493 (UCB)|
|Responsible Party:||Study Director, UCB|
|Other Study ID Numbers:||
|First Posted:||March 7, 2008 Key Record Dates|
|Last Update Posted:||November 15, 2013|
|Last Verified:||September 2009|
Central Nervous System Diseases
Nervous System Diseases